Replies to post #208481 on Anavex Life Sciences Corp (AVXL)

[seventhwave]

Yes, which is why Kauffman (the gatekeeper to the Rett community) was hired as the CMO and not an Alz. expert, though someone from the SAB/outside could take on a spot in 2021.

[nidan7500]

Doc, Missling is on record early on saying that he is going for the orphan Rett indication as the shortest path to approval for A2-73.

Approval in a first indication will be very good news for AD and other indications. Why prioritise the biggest and most challenging indication first if approval is more likely focusing with “High Priority” on Rett?

My understanding of his strategy is the same as yours. RSD first b/c of expense/support for and speed to get first results. I was a little surprised to see PDD jump out when it did.